• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    2seventy bio, Inc. - Common Stock (NQ: TSVT )

    3.360 -0.160 (-4.55%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 18, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 483,166
    Open 3.530
    Bid (Size) 3.350 (1)
    Ask (Size) 3.520 (30)
    Prev. Close 3.520
    Today's Range 3.310 - 3.585
    52wk Range 1.535 - 6.400
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    2seventy bio Reports Third Quarter Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    Earnings Scheduled For November 12, 2024
    Via Benzinga

    Performance

    YTD
    -18.05%
    -18.05%
    1 Month
    -32.39%
    -32.39%
    3 Month
    -28.96%
    -28.96%
    6 Month
    -23.29%
    -23.29%
    1 Year
    +93.10%
    +93.10%

    More News

    Read More
    2seventy bio Earnings Preview
    Via Benzinga
    2seventy bio to Report Third Quarter 2024 Financial Results and Participate in Upcoming Investor Conference
    From 2seventy bio, Inc.
    Via Business Wire
    Europe Drug Regulator's Advising Panel Recommends Approval Of Novo Nordisk's Australia-Approved Hemophilia Drug
    Via Benzinga
    TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Via Benzinga
    TSVT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into 2seventy bio, Inc. and Encourages Investors to Contact the Firm
    From Bronstein, Gewirtz & Grossman, LLC
    Via Business Wire
    Bristol Myers-2seventy Bio Halt Phase 3 Trial For Abecma In Newly Diagnosed Myeloma Patients, Speeds Path To Profitability
    Via Benzinga
    Exposures Product Safety
    2seventy bio Provides Update on KarMMa-9 Study and Previews Anticipated Strong Third Quarter Revenue Performance
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Participate in the 2024 Morgan Stanley Global Healthcare Conference
    From 2seventy bio
    Via Business Wire
    2seventy bio Reports Second Quarter Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Report Second Quarter 2024 Financial Results on August 7, 2024
    From 2seventy bio, Inc.
    Via Business Wire
    3 Hidden Stock Gems That Wall Street Is Overlooking
    Via InvestorPlace
    Novo Nordisk Buys 2seventy's Hemophilia A Program, Divestiture Supports Exclusive Focus On Abecma
    Via Benzinga
    2seventy bio Announces Sale of Hemophilia A Candidate and MegaTAL In Vivo Gene Editing Technology to Novo Nordisk for up to $40 million
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Participate in Upcoming Investor Conferences
    From 2seventy bio, Inc.
    Via Business Wire
    TSVT Stock Earnings: 2seventy bio Meets EPS, Misses Revenue for Q1 2024
    Via InvestorPlace
    2seventy bio Reports First Quarter Financial Results and Recent Operational Progress
    From 2seventy bio, Inc.
    Via Business Wire
    2seventy bio to Report First Quarter 2024 Financial Results on May 8, 2024
    From 2seventy bio, Inc.
    Via Business Wire
    FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
    Via Benzinga
    Exposures Product Safety
    FDA Approves Bristol-Myers/2seventy Bio's Abecma For Earlier Use In Pretreated Blood Cancer Patients With Updated Boxed Warning On Secondary Cancer
    Via Benzinga
    Exposures Product Safety
    2seventy bio Announces Completion of Oncology and Autoimmune Pipeline Divestiture to Regeneron
    From 2seventy bio, Inc.
    Via Business Wire
    U.S. FDA Approves Bristol Myers Squibb and 2seventy bio’s Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
    From Bristol Myers Squibb
    Via Business Wire
    2seventy bio Announces Appointments of Eli Casdin and Charles Newton to Board of Directors
    From 2seventy bio, Inc.
    Via Business Wire
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.